[424B3] PARKERVISION INC Prospectus Filed Pursuant to Rule 424(b)(3)

Rhea-AI Filing Summary

ParkerVision, Inc. has filed a prospectus supplement tied to an existing resale registration that permits selling stockholders to resell up to 5,871,584 shares of its common stock issued under prior securities purchase agreements. The company will not receive any proceeds from these resale transactions. The supplement updates the prospectus by incorporating a new Form 8-K.

The attached Form 8-K reports that on November 24, 2025, ParkerVision completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its shelf registration statement on Form S-3. The company conducted this primary offering without underwriters, placement agents, brokers, or finders and paid no commissions or fees.

Insights

Equity capital markets analyst

ParkerVision raised $3,461,132 via a direct common stock sale.

ParkerVision completed a primary offering of 16,481,579 shares of common stock to accredited investors at an aggregate purchase price of $3,461,132, using its effective Form S-3 shelf. This brings in new equity capital while relying on existing registration capacity, which can be important for an OTC-listed issuer with limited access to traditional underwritten offerings.

The transaction involved no underwriters, placement agents, brokers, or finders, so no commissions or fees were paid, meaning gross and net proceeds are the same in this excerpt. A separate, long-standing resale registration permits selling stockholders to resell up to 5,871,584 shares, which relates to previously issued shares rather than this new capital raise. Subsequent company filings may provide additional detail on how the new funds are used and any effects on the capital structure.

Filed pursuant to Rule 424(b)(3)

Registration No. 333-248242

PROSPECTUS SUPPLEMENT No. 62

(to Prospectus dated September 2, 2020)

PARKERVISION, INC.

5,871,584 Shares of Common Stock

This Prospectus Supplement relates to the prospectus dated September 2, 2020, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 5,871,584 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of an aggregate of 5,871,584 shares of Common Stock issued pursuant to securities purchase agreements dated April 29, 2020, May 22, 2020, June 8, 2020, June 29, 2020, July 24, 2020, and August 19, 2020.

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders.

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 24, 2025.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement.

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.”

You should read this prospectus and any prospectus supplement carefully before you invest in any of our securities.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 5 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

Neither the SEC nor any such authority has approved or disapproved these securities or determined whether this Prospectus or Prospectus Supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is November 25, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 24, 2025

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

Florida	000-22904	59-2971472
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida	32207
(Address of Principal Executive Offices)	(Zip Code)

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 8.01              Other Events.

On November 24, 2025, ParkerVision, Inc. (the “Company”) completed the offering and sale of 16,481,579 shares of its common stock, par value $0.01 per share (“Common Stock”), to accredited investors (the "Investors") for an aggregate purchase price of $3,461,132. 

The shares were issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-287427) and the prospectus supplement to be filed with the Securities and Exchange Commission (the “SEC”) on November 24, 2025, which contains the final terms of the offering.

The Company did not engage any underwriters, placement agents, brokers, or finders in connection with the transaction and paid no commissions or fees.

A copy of the Subscription Agreement was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 21, 2025.

On November 24, 2025, the Company issued a press release announcing the closing of the transaction.  A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit	Description
99.1	Press Release issued by ParkerVision on November 24, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 24, 2025

PARKERVISION, INC.

By /s/ Cynthia French

Cynthia French

Chief Financial Officer

FAQ

What does ParkerVision7s latest prospectus supplement for PRKR cover?

The prospectus supplement updates an existing resale registration that permits selling stockholders to resell up to 5,871,584 shares of ParkerVision common stock issued under prior securities purchase agreements. It incorporates by reference a new Form 8-K.

Does ParkerVision receive any proceeds from the 5,871,584 registered PRKR shares?

No. ParkerVision states that it will not receive proceeds from the sale of the 5,871,584 shares of common stock by the selling stockholders, since those are resale transactions of already issued shares.

What new equity financing did ParkerVision (PRKR) report on November 24, 2025?

ParkerVision reported completing the offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its Form S-3 shelf registration statement.

Were there any underwriting or placement fees in ParkerVision7s latest stock sale?

No. ParkerVision states that it did not engage underwriters, placement agents, brokers, or finders in connection with the 16,481,579-share transaction and paid no commissions or fees.

On which market is ParkerVision7s common stock (PRKR) listed?

ParkerVision7s common stock is listed on the OTCQB Venture Capital Market under the ticker symbol PRKR.

What key agreements or documents are associated with ParkerVision7s November 24, 2025 transaction?

The shares were issued under a Form S-3 shelf registration and a prospectus supplement containing the final terms. A Subscription Agreement was previously filed as Exhibit 10.1 to a Form 8-K dated November 21, 2025, and a related press release was filed as Exhibit 99.1 to the current Form 8-K.